Navigation Links
PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
Date:1/17/2012

Elder to the PAREXEL team of regulatory and strategic compliance experts reinforces our commitment to help clients proactively manage the risk of potential safety issues and product delays and failures on a global scale," said David L. Chesney, Vice President and Practice Lead, Strategic Compliance Services, PAREXEL Consulting.  "We expect that his extensive experience in conducting inspections and knowledge in areas such as global product safety and quality will greatly benefit our clients."

PAREXEL Consulting provides integrated product development consulting services, helping biopharmaceutical companies shorten time to market and maintain product viability for the long-term. Expertise provided by PAREXEL Consulting includes strategic regulatory partnering, product globalization, and development optimization, as well as solutions that deliver effective alignment of development and commercialization strategies. PAREXEL Consulting experts also provide capabilities in development of leading edge products such as biosimilars, therapeutic vaccines, and combination products. For information regarding PAREXEL Consulting's Strategic Compliance services visit http://www.PAREXELConsulting.com/services/strategic-compliance.html.

About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.&#
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Closes the Acquisition of ClinPhone
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
4. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
5. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
6. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
7. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
8. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
11. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Laboratory (IL) today announced that their Strategic Alliance ... June 22, 2012, after more than twenty successful ... direct sales, service, support and marketing to end-user ... own Hemostasis product line, including the HemosIL® line ...
... Pharmaceuticals today announced that the United States Patent and ... entitled, "Antibodies specific to heterodimers of Bcl-2 family and ... method for extending Eutropics, BH3 profiling technology, which is ... technology assesses the ability of a key part of ...
... 2012  Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... an update on the progress of Sangamo,s ZFP Therapeutic® development ... the following conferences: , The 11th Annual JMP ... PT (6:00 pm ET), on Monday, May 14, 2012. ...
Cached Biology Technology:Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 2Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 3Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method 2Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... of a gene that optimizes their brain's thinking circuitry, ... severe mental illness marked by impaired thinking, scientists at ... Mental Health (NIMH) have discovered. The seeming paradox ... of variation in the human gene for a brain ...
... of epicatechin, a compound found in cocoa, are so striking ... importance to public health, reports Marina Murphy in Chemistry & ... medicine at Harvard Medical School, told C&I that epicatechin is ... , Hollenberg has spent years studying the benefits of cocoa ...
... Researchers from Université Laval’s Faculty of Medicine have ... antiwrinkle products causes a pathological reaction in skin ... present their conclusions about the mode of action ... the British Journal of Dermatology. , DMAE (2-dimethylaminoethanol) ...
Cached Biology News:Common gene version optimizes thinking -- but with a possible downside 2Cocoa 'vitamin' health benefits could outshine penicillin 2Anti-wrinkle compound causes pathological reaction in skin cells 2
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
DONOR BOVINE SERUM AND PLASMA...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: